Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 12, 2015, Pages

  Singh, Neetu ^a   Halliday, Henry L ^b   Stevens, Timothy P ^c   Suresh, Gautham ^a   Soll, Roger ^d   Rojas Reyes, Maria Ximena ^e  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d UNIVERSITY OF VERMONT   (United States)

^e PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE LUNG LAVAGE SURFACTANT EXTRACT; LUNG SURFACTANT; LUNG SURFACTANT EXTRACT; MODIFIED BOVINE MINCED LUNG SURFACTANT EXTRACT; UNCLASSIFIED DRUG;

AIR LEAK SYNDROME; BACTERIAL INFECTION; BACTERIUM CULTURE; BRAIN HEMORRHAGE; CHILD DEATH; CHRONIC LUNG DISEASE; DISEASE SEVERITY; HOSPITAL DISCHARGE; HUMAN; LEUKOMALACIA; LUNG HEMORRHAGE; LUNG LAVAGE; MORTALITY RISK; NECROTIZING ENTEROCOLITIS; NEUROIMAGING; NEWBORN DISEASE; NEWBORN MORTALITY; OUTCOME ASSESSMENT; OXYGEN CONSUMPTION; PATENT DUCTUS ARTERIOSUS; PNEUMOTHORAX; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RETINOPATHY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SYSTEMATIC REVIEW; ANIMAL; BOVINE; META ANALYSIS; MORTALITY; NEWBORN; OXYGEN THERAPY; PIG; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY DISTRESS SYNDROME, NEWBORN;

ANIMALS; CATTLE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; OXYGEN INHALATION THERAPY; PULMONARY SURFACTANTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY DISTRESS SYNDROME, NEWBORN; SWINE;

EID: 84965188368     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010249.pub2     Document Type: Review

References (63)

1. Attar MA, Becker MA, Dechert RE. Immediate change in lung compliance following natural surfactant administration in premature infants with respiratory distress syndrome. Journal of Perinatology 2004;24(10):626-30.
2. Baroutis G, Kaleyias J, Liarou T. Comparison of three treatment regimens of the natural surfactant preparations in neonatal respiratory distress syndrome. European Journal of Pediatrics 2003;162(7-8):476-80.
3. Bloom BT, Kattwinkel J, Hall RT, Delmore PM, Egan EA, Trout JR, et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics 1997;100(1):31-8.
4. Bloom BT, Clark RH for Infasurf Survanta Clinical Trial group. Comparision of Infasurf (calfactant) and Survanta (beractant) in the prevention of respiratory distress syndrome. Pediatrics 2005;116(2):392-9.
5. Dizdar EA, Sari FN, Aydemir C, Oguz SS, Erdeve O, Uras N, et al. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome. American Journal of Perinatology 2012;29(2):95-100.
6. Fujii AM, Patel SM, Allen R. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome. Journal of Perinatology 2010;30(10):665-70.
7. Gharehbaghi MM, Sakha SH, Ghojazadeh M, Firoozi F. Complications among premature neonates treated with beractant and poractant alfa. Indian Journal of Pediatrics 2010;77(7):751-4.
8. Halahakoon WL. A study of cerebral function following surfactant treatment for respiratory distress syndrome (Doctoral dissertation). Queen's University of Belfast (UK) 1999.
9. Hammoud M, Al-Kazmi N, Alshemmiri M, Thalib L, Ranjani VT, Devarajan LV, et al. Randomized clinical trial comparing two natural surfactant preparations to treat respiratory distress syndrome. Journal of Maternal Fetal and Neonatal Medicine 2004;15(3):167-75.
10. Karadag N, Dilli D, Zenciroglu A, Aydin B, Beken S, Okumus N. Perfusion index variability in preterm infants treated with two different natural surfactants for respiratory distress syndrome. American Journal of Perinatology 2014;31(11):1015-22. [PUBMED: 24566756]
11. Lam BC, Ng YK, Wong KY. Randomized trial comparing two natural surfactants (Survanta vs bLES) for treatment of neonatal respiratory distress syndrome. Pediatric Pulmonology 2005;39(1):64-9.
12. Malloy CA, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatrica 2005;94(6):779-84.
13. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K, North American Study Group. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. American Journal of Perinatology 2004;21(3):109-19.
14. Sánchez-Mendiola M, Martínez-Natera OC, Herrera-Maldonado N, Ortega-Arroyo J. Treatment of hyaline membrane disease in the preterm newborn with exogenous lung surfactant: a controlled study [Estudio controlado del tratamiento de la enfermedad de membrana hialina del recien nacido pretermino con surfactante pulmonar exogeno (porcino vs bovino)]. Gaceta medica Mexico 2005;141(4):267-71.
15. Speer CP, Gefeller O, Groneck P. Randomized clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Archives of Disease in Childhood 1995;72(1):F8-13.
16. Yalaz M, Aslanoglu S, Akisu M, Atik T, Ergun O, Kultursay N. A comparison of efficacy between two natural exogenous surfactant preparations in premature infants with respiratory distress syndrome. Klinische Padiatrie 2004;216(4):230-5.
17. Bozdağ S, Dilli D, Gökmen T, Dilmen U. Comparison of two natural surfactants for pulmonary hemorrhage in very low-birth-weight infants: a randomized controlled trial. American Journal of Perinatology 2015;32(3):211-8.
18. Choi CW, Hwang JH, Yoo EJ, Kim KA, Koh SY, Lee YK, et al. Comparison of clinical efficacy of Newfactan versus Surfacten for the treatment of respiratory distress syndrome in he newborn infants. Journal of Korean Medical Science 2005;20(4):591-7.
19. Proquitté H, Dushe T, Hammer H, Rüdiger M, Schmalisch, G, Wauer RR, et al. Observational study to compare the clinical efficacy of the natural surfactants Alveofact and Curosurf in the treatment of respiratory distress syndrome in premature infants. Respiratory Medicine 2007;101(1):169-76.
20. Rebello CM, Mascaretti RS, Precioso AR. A multicenter randomized double blind trial of a new low cost animal surfactant in premature infants with respiratory distress syndrome. E-PAS. 2009.
21. Rebello CM, Precioso AR, Mascaretti RS, Grupo Colaborativo do Estudo Brasileiro Multicêntrico de Surfactante. A multicenter, randomized, double-blind trial of a new porcine surfactant in premature infants with respiratory distress syndrome. Einstein (Sao Paulo) 2014;12(4):397-404. [DOI: 10.1590/S1679-45082014AO3095]
22. Eras Z, Dizdar EA, Kanmaz G, Guzoglu N, Aksoy HT, Altunkaya GB, et al. Neurodevelopmental outcomes of very low birth weight preterm infants treated with poractant alfa versus beractant for respiratory distress syndrome. American Journal of Perinatology 2014;31(6):463-8. [DOI: 10.1055/s-0033-1351659]
23. Gharehbaghi MM, Yasrebi S. Comparing the efficacy of two natural surfactants, Curosurf and Alveofact, in treatment of respiratory distress syndrome in preterm infants. International Journal of Women's Health and Reproduction Sciences 2014;2(4):245-8.
24. Mercado VV, Cristea I, Ali N, Pham CC, Buescher E, Yang J, et al. Does surfactant type cause a differential proinflammatory response in preterm infant with respiratory distress syndrome?. Advances in Therapy 2010;27(7):476-82.
25. Saeidi R, Hamedi A, Javadi A, Robatsangi MG, Dinparvar SK. Comparison of side effects of survanta and curosurf in decreasing mortality due to respiratory distress syndrome (RDS) in premature infants admitted in NICU of Ghaem Hospital on 2006-2008. Iranian Journal of Neonatology 2013;4(3):7-12. [AN:2013708341]
26. Terek D, Gonulal D, Koroglu OA, Yalaz M, Akisu M, Kultursay N. Effects of two different exogenous surfactant preparations on serial peripheral perfusion index and tissue carbon monoxide measurements in preterm infants with severe respiratory distress syndrome. Pediatric Neurology 2015;56(4):248-55.
27. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. American Journal of Diseases in Children 1959;97(5 Pt 1):517-23.
28. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Annals of Surgery 1978;187(1):1-7.
29. Chu J, Clements JA, Cotton EK, Klaus MH, Sweet AY, Tooley WH. Neonatal pulmonary ischemia. I. Clinical and physiological studies. Pediatrics 1967;40(4):709-82.
30. Dargaville PA, Aiyappan A, Cornelius A, Williams C, Antonio G De Paoli. Preliminary evaluation of a new technique of minimally invasive surfactant therapy. Archive of Disease in Childhood -Fetal and Neonatal Edition 2011;96(4):F243-8.
31. Engle WA, American Academy of Pediatrics Committee on Fetus and Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics 2008;121(2):419-32.
32. Enhorning G, Robertson B. Lung expansion in the premature rabbit fetus after tracheal deposition of surfactant. Pediatrics 1972;50(1):58-66.
33. Fujiwara T, Maeta H, Chida S, Morita T, Watabe YJ, Abe T. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980;I(8159):55-9.
34. Jan Brozek, Andrew Oxman, Holger Schünemann. GradePro [Version 3.2 for Windows]. 2008.
35. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of clinical epidemiology 2011;64(4):383-94. [PUBMED: 21195583]
36. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407-15. [PUBMED: 21247734]
37. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. Journal of clinical epidemiology 2011;64(12):1283-93. [PUBMED: 21839614]
38. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. Journal of clinical epidemiology 2011;64(12):1294-302. [PUBMED: 21803546]
39. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence--indirectness. Journal of clinical epidemiology 2011;64(12):1303-10. [PUBMED: 21802903]
40. Halliday HL. Surfactants: past, present and future. Journal of Perinatology 2008;28(Suppl 1):S47-S56.
41. Hawgood S, Benson BJ, Hamilton Jr. RL. Effects of surfactant-associated proteins and calcium ions on the structure and surface activity of lung surfactant lipids. Biochemistry 1985;24(1):184-90.
42. Higgins A, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
43. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Archives of Ophthalmology 2005;123(7):991-9.
44. Jobe AH. Pulmonary surfactant therapy. New England Journal of Medicine 1993;328(1):861-8.
45. Kribs A, Pillekamp F, Hunseler C. Early administration of surfactant in spontaneous breathing with nCPAP: feasibility and outcome in extremely premature infants (postmenstrual age < 27 weeks). Pediatric Anesthesia 2007;17(4):364-9.
46. Logan JW, Moya FR. Animal derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: summary of clinical trials. Therapeutic and Clinical Risk Management 2009;5(1):251-60.
47. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1, 500 gm. Journal of Pediatrics 1978;92(4):529-34.
48. Pfister RH, Soll RF, Wiswell T. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD006069.pub3]
49. Pfister RH, Soll R, Wiswell TE. Protein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD006180.pub2]
50. Ramanathan R. Animal derived surfactants: where are we? The evidence from randomized controlled trials. Journal of Perinatology 2009;29(Suppl 2):s38-43.
51. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
52. Robillard E, Alarie Y, Dagenais-Perusse P, Baril E, Guilbeault A. Microaerosol administration of synthetic beta-gamma-dipalmitoyl-L-alpha-lecithin in the respiratory distress syndrome. Canadian Medical Association Journal 1964;90:55-7.
53. Rojas-Reyes MX, Morley CJ, Soll R. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews 2012, Issue 3. [DOI: 10.1002/14651858.CD000510.pub2]
54. Schünemann H, Brozek J, Guyatt G, Oxman A, editors. The GRADE Working Group. GRADE handbook for grading quality of evidence and strength of recommendations. Available from www.guidelinedevelopment.org/handbook. Updated October 2013.
55. Seger N, Soll R. Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007836]
56. Singh N, Hawley KL, Viswanathan K. Efficacy of porcine versus bovine surfactants for preterm newborns with respiratory distress syndrome: systematic review and meta-analysis. Pediatrics 2011;128(6):e1588-95.
57. Soll RF, McQueen MC. Respiratory Distress Syndrome. Sinclair J, Bracken M: Effective Care of the Newborn Infant. New York: Oxford University Press, 1992:325-58. [ISBN 0-19-261737-0]
58. Soll R, Özek E. Prophylactic animal derived surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews 1997, Issue 4. [DOI: 10.1002/14651858.CD000511]
59. Soll R. Synthetic surfactant for respiratory distress syndrome in preterm infants. Cochrane Database of Systematic Reviews 1998, Issue 3. [DOI: 10.1002/14651858.CD001149]
60. Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: 10.1002/14651858.CD000144]
61. Soll R, Özek E. Prophylactic animal derived surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews 1997, Issue 4. [DOI: 10.1002/14651858.CD000511]
62. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants--2013 update. Neonatology 2013;103(4):353-68.
63. Whitsett JA, Nogee LM, Weaver TE, Horowitz AD. Human surfactant protein B: structure, function, regulation, and genetic disease. Physiological Reviews 1995;75(4):749-57.